{"id":25272,"date":"2016-04-01T10:57:32","date_gmt":"2016-04-01T08:57:32","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=25272"},"modified":"2016-04-01T18:11:22","modified_gmt":"2016-04-01T16:11:22","slug":"novartis-su-presunte-tangenti-turchia-indagheremo-a-fondo","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/novartis-su-presunte-tangenti-turchia-indagheremo-a-fondo\/","title":{"rendered":"Novartis on T\u00fcrkiye alleged bribes, we will investigate thoroughly"},"content":{"rendered":"

To \u201censure compliance, the promotional activities of the marketing and sales structures operating locally are regularly checked. Novartis associates who suspect misconduct should report it to our Business Practices Officer.\u201d The company also clarifies the US investigation<\/em><\/p>\n

Margherita Lopes \u2013 01\/04\/2016 \u2013 PharmaKronos<\/em><\/span><\/a><\/p>\n

\"\"On the alleged case of payment of bribes to the Turkish authorities reported by the press, Novartis assures that "it will take all allegations of inappropriate behavior extremely seriously and will investigate thoroughly". To \u201censure compliance, the promotional activities of the marketing and sales structures operating locally are regularly checked. Novartis associates who suspect an episode of misconduct are required to report it to our Business Practices Officer.<\/p>\n

However, the company "will not disclose any comments on these investigations, even if the person filing the complaint decides to make them public". And she says she is \u201ccommitted to conducting marketing and sales activities in compliance with high quality and ethical standards. This commitment is fundamental, not only to be able to guarantee the appropriate and effective use of the products and services by healthcare professionals and patients, but also to protect the Group's reputation and credibility". As for the ongoing investigation by the American authorities, for alleged bribes to the medical-scientific class, Novartis specifies that the American branch Novartis Pharmaceuticals Corporation (NPC) "requested a preliminary hearing, in relation to the forwarding of a request for precautionary measure in the civil case, which concerns some training programs that the company conducted in the period from 2002 to 2011\u201d.<\/p>\n

\"\"Npc has forwarded \u201ca request for a precautionary measure, because the Government has asked the company to also present documents that go beyond the scope of the protocols and that go beyond the previously agreed terms; the production of these documents would now be excessively complex, (particularly considering the timescales set by the Court),\u201d says the company. Npc therefore contests the way in which the institutions have represented its conduct in relation to these issues, as well as contesting the accusations made by the Government.<\/p>\n

\u201cNpc is committed to ensuring that doctors and patients have the information they need to make informed decisions about the health of their patients; it also believes that educational programs can help educate more healthcare professionals on the appropriate use of medicines, helping them to prescribe based on adequate information, which in turn improves patient care. Novartis \u2013 concludes the note \u2013 will continue to conduct its business in an ethical manner and in compliance with laws and regulations\u201d.<\/p>\n

Related news: USA. The investigation against Novartis extends. Bribes also to the Turkish authorities? $ 25 million fine for corruption in China<\/span><\/a><\/p>\n

Novartis, the shadow of bribes. An anonymous whistleblower has accused the Swiss drugmaker of bribing a company in Turkey<\/span><\/a><\/p>\n

T\u00fcrkiye: Ankara prosecutor opens investigation into Novartis branch<\/span><\/a><\/p>\n

 <\/p>","protected":false},"excerpt":{"rendered":"

Per “garantire la compliance, vengono verificate regolarmente le attivit\u00e0 promozionali delle strutture di marketing e vendita operanti a livello locale. I collaboratori di Novartis che sospettano un episodio di cattiva condotta sono tenuti a segnalarlo al nostro Business Practices Officer”. L\u2019azienda chiarisce anche su inchiesta Usa Margherita Lopes – 01\/04\/2016 – PharmaKronos Sul presunto caso …<\/p>","protected":false},"author":4,"featured_media":25276,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[41,54,22],"class_list":["post-25272","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-leggisentenze","tag-marketing","tag-truffa-farmaci"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/25272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=25272"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/25272\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/25276"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=25272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=25272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=25272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}